苯并[D]恶唑-7-胺 | 136992-95-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 中文名称: 苯并[D]恶唑-7-胺
• 英文名称: benzo[d]oxazol-7-amine
• 英文别名: benzooxazol-7-amine；Benzo[d]oxazol-7-amine；1,3-benzoxazol-7-amine
• CAS: 136992-95-5
• 化学式: C₇H₆N₂O
• 分子量: 134.137
• InChiKey: RYXAABPGJZPRIP-UHFFFAOYSA-N

物化性质

• 沸点：
  282.3±13.0 °C(Predicted)
• 密度：
  1.317±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P280
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  苯并[D]恶唑-7-胺 在 tris-(dibenzylideneacetone)dipalladium(0) 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 生成 N'-benzooxazol-7-yl-N-(3,5-dimorpholin-4-ylphenyl)pyrimidine-2,4-diamine
  参考文献：
  名称：

  PYRIMIDINE DERIVATIVES

  摘要：

  这项发明涉及Formula (I)的苯甲酰胺化合物或其药用可接受的盐，其中R1、环A、n、R3和R4如描述中所定义。本发明还涉及制备这种化合物的方法、含有它们的药物组合物以及它们在制造用作抗增殖剂的药物中的用途，用于预防或治疗对EphB4、EphA2和/或Src激酶抑制敏感的肿瘤或其他增殖病症。

  公开号：

  US20110046108A1
• 作为产物：
  描述：

  7-nitrobenzoxazole 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙酸乙酯 为溶剂， 以100%的产率得到苯并[D]恶唑-7-胺
  参考文献：
  名称：

  [EN] NOVEL P2X7 RECEPTOR ANTAGONISTS
  [FR] NOUVEAUX ANTAGONISTES DU RÉCEPTEUR P2X7

  摘要：

  The invention relates generally to a compound of Formula (I), wherein R1is a bicyclic fused heterocyclic moiety and R2is H or F. The compound of Formula (I) or a pharmaceutically acceptable salt thereof has potential medical use in the treatment or prevention of conditions such as stroke; amyotrophic lateral sclerosis; multiple sclerosis; Alzheimer s disease; Huntington s disease, atherosclerosis, diabetic retinopathy; dilated cardiomyopathy; ischemic injury and left ventricular hypertrophy post myocardial infarction.

  公开号：

  WO2023092175A1

文献信息

• Optimization of 4-Anilinoquinolines as Dengue Virus Inhibitors
  作者：Pei-Tzu Huang、Sirle Saul、Shirit Einav、Christopher R. M. Asquith

  DOI：10.3390/molecules26237338

  日期：——

  Emerging viral infections, including those caused by dengue virus (DENV) and Venezuelan Equine Encephalitis virus (VEEV), pose a significant global health challenge. Here, we report the preparation and screening of a series of 4-anilinoquinoline libraries targeting DENV and VEEV. This effort generated a series of lead compounds, each occupying a distinct chemical space, including 3-((6-bromoquinolin-4-yl)amino)phenol (12), 6-bromo-N-(5-fluoro-1H-indazol-6-yl)quinolin-4-amine (50) and 6-((6-bromoquinolin-4-yl)amino)isoindolin-1-one (52), with EC50 values of 0.63–0.69 µM for DENV infection. These compound libraries demonstrated very limited toxicity with CC50 values greater than 10 µM in almost all cases. Additionally, the lead compounds were screened for activity against VEEV and demonstrated activity in the low single-digit micromolar range, with 50 and 52 demonstrating EC50s of 2.3 µM and 3.6 µM, respectively. The promising results presented here highlight the potential to further refine this series in order to develop a clinical compound against DENV, VEEV, and potentially other emerging viral threats.

  新兴病毒感染，包括那些由登革热病毒（DENV）和委内瑞拉马脑炎病毒（VEEV）引起的感染，构成了全球重大的健康挑战。在这里，我们报告了针对DENV和VEEV的一系列4-苯胺基喹啉类化合物库的制备和筛选工作。这一努力产生了一系列主导化合物，每个化合物占据着不同的化学空间，包括3-((6-溴喹啉-4-基)氨基)酚（12）、6-溴-N-(5-氟-1H-吲哚-6-基)喹啉-4-胺（50）和6-((6-溴喹啉-4-基)氨基)异吲哚啉-1-酮（52），对DENV感染的EC50值为0.63-0.69 µM。这些化合物库在几乎所有情况下表现出非常有限的毒性，CC50值大于10 µM。此外，主导化合物被筛选用于对抗VEEV，并在低个位数微摩尔范围内展示了活性，其中50和52的EC50分别为2.3 µM和3.6 µM。这里呈现的有希望的结果突显了进一步完善这一系列的潜力，以开发针对DENV、VEEV和潜在其他新兴病毒威胁的临床化合物。
• [EN] PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE PYRAZOLOPYRIMIDINONE ET LEURS UTILISATIONS
  申请人：ADURO BIOTECH INC

  公开号：WO2019055750A1

  公开（公告）日：2019-03-21

  The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

  本发明涉及吡唑吡咪啉酮化合物。本发明还涉及含有这些化合物的药物组合物，以及通过向需要的受试者施用这些化合物和药物组合物来治疗自身免疫、炎症和神经退行性疾病的方法。本发明还涉及利用这些化合物进行研究或其他非治疗目的的用途。
• Towards the Development of an In vivo Chemical Probe for Cyclin G Associated Kinase (GAK)
  作者：Christopher R. M. Asquith、James M. Bennett、Lianyong Su、Tuomo Laitinen、Jonathan M. Elkins、Julie E. Pickett、Carrow I. Wells、Zengbiao Li、Timothy M. Willson、William J. Zuercher

  DOI：10.3390/molecules24224016

  日期：——

  SGC-GAK-1 (1) is a potent, selective, cell-active chemical probe for cyclin G-associated kinase (GAK). However, 1 was rapidly metabolized in mouse liver microsomes by cytochrome P450-mediated oxidation, displaying rapid clearance in liver microsomes and in mice, which limited its utility in in vivo studies. Chemical modifications of 1 that improved metabolic stability, generally resulted in decreased GAK potency. The best analog in terms of GAK activity in cells was 6-bromo-N-(1H-indazol-6-yl)quinolin-4-amine (35) (IC50 = 1.4 μM), showing improved stability in liver microsomes while still maintaining a narrow spectrum activity across the kinome. As an alternative to scaffold modifications we also explored the use of the broad-spectrum cytochrome P450 inhibitor 1-aminobenzotriazole (ABT) to decrease intrinsic clearance of aminoquinoline GAK inhibitors. Taken together, these approaches point towards the development of an in vivo chemical probe for the dark kinase GAK.

  SGC-GAK-1 (1)是一种针对cyclin G相关激酶（GAK）的有效、选择性、细胞活性化学探针。然而，在小鼠肝微粒体中，1通过细胞色素P450介导的氧化迅速代谢，导致在肝微粒体和小鼠中迅速清除，从而限制了其在体内研究中的实用性。对1的化学修饰改善了代谢稳定性，但通常导致GAK效力降低。在细胞中GAK活性方面效果最好的类似物是6-溴-N-(1H-吲唑-6-基)喹啉-4-胺（35）（IC50 = 1.4 μM），在肝微粒体中显示出改善的稳定性，同时仍保持着在激酶组中的狭谱活性。作为对骨架修饰的替代方案，我们还探索了广谱细胞色素P450抑制剂1-氨基苯并三唑（ABT）的使用，以降低氨基喹啉GAK抑制剂的内在清除率。综合考虑这些方法，指向了开发一种针对暗激酶GAK的体内化学探针的方向。
• Kinase inhibitors as therapeutic agents
  申请人：Cusack Kevin

  公开号：US20060074102A1

  公开（公告）日：2006-04-06

  A compound or pharmaceutically acceptable salts thereof of Formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.

  式(I)化合物或其药学上可接受的盐，其中取代基如本文所定义，可用作激酶抑制剂。
• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：KAYOTHERA INC

  公开号：WO2022226383A1

  公开（公告）日：2022-10-27

  Provided herein are novel heterocyclic compounds, for example, compounds having Formula I, I-P, II, II-P, III, or IV. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases, retinoid pathway activation, and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH) or as a male contraceptive.

  本文提供了新型杂环化合物，例如具有I、I-P、II、II-P、III或IV式的化合物。本文还提供了包含这些化合物的制药组合物以及使用它们的方法，例如在抑制醛脱氢酶、视黄醇途径激活和/或治疗各种癌症、癌症转移、2型糖尿病、肺动脉高压（PAH）或新内膜增生（NIH）或作为男性避孕药物。